# CAPR — Capricor Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CAPR  
**Sources:** 23  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-capr-capricor-therapeutics-inc-catalysts-narrative-risks-10541

---

# Capricor Therapeutics, Inc. (NASDAQ: CAPR) — Point-in-Time Research (as of 2026-11-01)

## Recent Catalysts (roughly August–October 2026)

The dominant recent catalysts revolve around the regulatory saga of Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD):

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-capr-capricor-therapeutics-inc-catalysts-narrative-risks-10541 (free to sign up)._